Literature DB >> 18781606

Evaluation of chemical degradation of a trivalent recombinant protein vaccine against botulinum neurotoxin by LysC peptide mapping and MALDI-TOF mass spectrometry.

Tia Estey1, Christina Vessely, Theodore W Randolph, Ian Henderson, Latoya Jones Braun, Rajiv Nayar, John F Carpenter.   

Abstract

Vaccines utilizing recombinant protein antigens typically require an adjuvant to enhance immune response in the recipients. However, the consequences of antigen binding to adjuvant on both the short- and long-term stability of the protein remain poorly defined. In our companion paper (Vessely et al., in press, J Pharm Sci), we characterized the effects of binding to adjuvant on the conformation and thermodynamic stability of three antigen variants for botulinum vaccines: rBoNTA(H(c)), rBoNTB(H(c)), and rBoNTE(H(c)). In the current study, we evaluated the effect of binding to adjuvant (Alhydrogel, aluminum hydroxide) on chemical stability of these antigens during long-term storage in aqueous suspension. We developed methods that employ LysC peptide mapping in conjunction with MALDI-TOF mass spectrometry. Peptide maps were developed for the proteins for a vaccine formulation of rBoNTE(H(c)) as well as a trivalent rBoNT(H(c)) vaccine formulation. This method provided high sequence coverage for the proteins in part due to the implementation of a postdigestion elution fractionation method during sample preparation, and was also successfully utilized to evaluate the chemical integrity of adjuvant-bound rBoNT(H(c)) protein antigens. We found that all three of the rBoNT(H(c)) proteins were susceptible to degradation via both oxidation and deamidation. In many cases, such reactions occurred earlier with the adjuvant-bound protein formulations when compared to the proteins in control samples that were not bound to adjuvant. Additionally, some chemical modifications were found in the adjuvant-bound protein formulations but were not detected in the unbound solution controls. Our studies indicate that binding to aluminum-based adjuvants can impact the chemical stability and/or the chemical degradation pathways of protein during long-term storage in aqueous suspension. Furthermore, the methods we developed should be widely useful for assessing chemical stability of adjuvant-bound recombinant protein antigens.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 18781606      PMCID: PMC2721025          DOI: 10.1002/jps.21543

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  30 in total

Review 1.  Recent developments in adjuvants for vaccines against infectious diseases.

Authors:  D T O'Hagan; M L MacKichan; M Singh
Journal:  Biomol Eng       Date:  2001-10-15

Review 2.  Preformulation studies as an essential guide to formulation development and manufacture of protein pharmaceuticals.

Authors:  David B Volkin; Gautam Sanyal; Carl J Burke; C Russell Middaugh
Journal:  Pharm Biotechnol       Date:  2002

Review 3.  Aluminium adjuvants--in retrospect and prospect.

Authors:  Erik B Lindblad
Journal:  Vaccine       Date:  2004-09-09       Impact factor: 3.641

Review 4.  Analysis of posttranslational modifications of proteins by tandem mass spectrometry.

Authors:  Martin R Larsen; Morten B Trelle; Tine E Thingholm; Ole N Jensen
Journal:  Biotechniques       Date:  2006-06       Impact factor: 1.993

5.  Identification of the protein receptor binding site of botulinum neurotoxins B and G proves the double-receptor concept.

Authors:  Andreas Rummel; Timo Eichner; Tanja Weil; Tino Karnath; Aleksandrs Gutcaits; Stefan Mahrhold; Konrad Sandhoff; Richard L Proia; K Ravi Acharya; Hans Bigalke; Thomas Binz
Journal:  Proc Natl Acad Sci U S A       Date:  2006-12-21       Impact factor: 11.205

6.  Effects of adsorption to aluminum salt adjuvants on the structure and stability of model protein antigens.

Authors:  LaToya S Jones; Laura J Peek; Jonathan Power; Aaron Markham; Brian Yazzie; C Russell Middaugh
Journal:  J Biol Chem       Date:  2005-01-31       Impact factor: 5.157

7.  Oxidation of methionine residues in recombinant human interleukin-1 receptor antagonist: implications of conformational stability on protein oxidation kinetics.

Authors:  Renuka Thirumangalathu; Sampathkumar Krishnan; Pavel Bondarenko; Margaret Speed-Ricci; Theodore W Randolph; John F Carpenter; David N Brems
Journal:  Biochemistry       Date:  2007-05-05       Impact factor: 3.162

8.  Biodegradable and biocompatible poly(DL-lactide-co-glycolide) microspheres as an adjuvant for staphylococcal enterotoxin B toxoid which enhances the level of toxin-neutralizing antibodies.

Authors:  J H Eldridge; J K Staas; J A Meulbroek; T R Tice; R M Gilley
Journal:  Infect Immun       Date:  1991-09       Impact factor: 3.441

9.  Effects of solution conditions and surface chemistry on the adsorption of three recombinant botulinum neurotoxin antigens to aluminum salt adjuvants.

Authors:  Christina Vessely; Tia Estey; Theodore W Randolph; Ian Henderson; Rajiv Nayar; John F Carpenter
Journal:  J Pharm Sci       Date:  2007-09       Impact factor: 3.534

10.  Localization of the regions on the C-terminal domain of the heavy chain of botulinum A recognized by T lymphocytes and by antibodies after immunization of mice with pentavalent toxoid.

Authors:  J S Rosenberg; J L Middlebrook; M Z Atassi
Journal:  Immunol Invest       Date:  1997-06       Impact factor: 3.657

View more
  11 in total

Review 1.  A rational, systematic approach for the development of vaccine formulations.

Authors:  Garry L Morefield
Journal:  AAPS J       Date:  2011-02-23       Impact factor: 4.009

2.  Working together: interactions between vaccine antigens and adjuvants.

Authors:  Christopher B Fox; Ryan M Kramer; Lucien Barnes V; Quinton M Dowling; Thomas S Vedvick
Journal:  Ther Adv Vaccines       Date:  2013-05

3.  Glassy-state stabilization of a dominant negative inhibitor anthrax vaccine containing aluminum hydroxide and glycopyranoside lipid A adjuvants.

Authors:  Kimberly J Hassett; David J Vance; Nishant K Jain; Neha Sahni; Lilia A Rabia; Megan C Cousins; Sangeeta Joshi; David B Volkin; C Russell Middaugh; Nicholas J Mantis; John F Carpenter; Theodore W Randolph
Journal:  J Pharm Sci       Date:  2015-01-11       Impact factor: 3.534

4.  Stabilization of a recombinant ricin toxin A subunit vaccine through lyophilization.

Authors:  Kimberly J Hassett; Megan C Cousins; Lilia A Rabia; Chrystal M Chadwick; Joanne M O'Hara; Pradyot Nandi; Robert N Brey; Nicholas J Mantis; John F Carpenter; Theodore W Randolph
Journal:  Eur J Pharm Biopharm       Date:  2013-04-10       Impact factor: 5.571

Review 5.  Vaccines with aluminum-containing adjuvants: optimizing vaccine efficacy and thermal stability.

Authors:  Tanya Clapp; Paul Siebert; Dexiang Chen; LaToya Jones Braun
Journal:  J Pharm Sci       Date:  2010-08-25       Impact factor: 3.534

6.  Stability of a trivalent recombinant protein vaccine formulation against botulinum neurotoxin during storage in aqueous solution.

Authors:  Christina Vessely; Tia Estey; Theodore W Randolph; Ian Henderson; Julianne Cooper; Rajiv Nayar; Latoya Jones Braun; John F Carpenter
Journal:  J Pharm Sci       Date:  2009-09       Impact factor: 3.534

7.  Structural and functional modifications of corneal crystallin ALDH3A1 by UVB light.

Authors:  Tia Estey; Ying Chen; John F Carpenter; Vasilis Vasiliou
Journal:  PLoS One       Date:  2010-12-21       Impact factor: 3.240

8.  The mechanisms of action of vaccines containing aluminum adjuvants: an in vitro vs in vivo paradigm.

Authors:  Tirth Raj Ghimire
Journal:  Springerplus       Date:  2015-04-16

Review 9.  Optimizing the utilization of aluminum adjuvants in vaccines: you might just get what you want.

Authors:  Harm HogenEsch; Derek T O'Hagan; Christopher B Fox
Journal:  NPJ Vaccines       Date:  2018-10-10       Impact factor: 7.344

10.  Mechanism of immunopotentiation and safety of aluminum adjuvants.

Authors:  Harm Hogenesch
Journal:  Front Immunol       Date:  2013-01-10       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.